<HashMap><database>ENA</database><scores/><additional><omics_type>Genomics</omics_type><center_name>NEWCASTLE UNIVERSITY, UK</center_name><full_dataset_link>https://www.ebi.ac.uk/ena/browser/view/PRJEB39670</full_dataset_link><tag>xref:EuropePMC:PMC8883198</tag><tag>xref:PubMed:35243393</tag><tag>xref:PubMed:36480295</tag><long_description>Background: AnTIC trial data showed continuous low-dose antibiotic prophylaxis to be effective in reducing symptomatic urinary tract infections (UTIs) compared to no treatment, in clean intermittent self-catheterisation (CISC) users. Antibiotic prophylaxis was however associated with increased antibiotic resistance. The mechanisms by which prophylaxis benefitted such patients are not known. Prophylactic treatments involving β-lactam based antibiotics and nitrofurantoin appeared to select against E. coli. However, 17 patients were characterised by uro-associated E.coli that acquired multi drug resistance (MDR) during the trial. Sequencing of these E. coli isolates, associated with bacterial loads (>104 CFU/ml), showed patients prescribed prophylactic antibiotics tended to harbour one E. coli strain while patients in the non-prophylactic study arm were colonised by >1 E. coli strain. Interpretation: These findings suggest that continuous low-dose antibiotic treatments in some CISC patients selected for MDR bacteria, which resulted in a stable personalised uromicrobiota and a lower rate of symptomatic UTIs.</long_description><repository>ENA</repository></additional><is_claimable>false</is_claimable><name>AnTIC_Ecoli</name><description>AnTIC: Uro-associated E. coli Genome Analysis</description><dates><last_updated>2025-01-27</last_updated><first_public>2021-01-05</first_public></dates><accession>PRJEB39670</accession><cross_references><PubMed>36480295</PubMed><PubMed>35243393</PubMed></cross_references></HashMap>